Enhanced Mesenchymal Stem Cell-Derived Exosomes for Immune-Mediated Inflammatory Diseases

The present inventive concept relates to improved mesenchymal stem cell-derived exosomes for treating immune-mediated inflammatory diseases, offering enhanced efficacy, targeted delivery, and monitoring capabilities.

The original patent disclosed the use of mesenchymal stem cell-derived exosomes for treating immune-mediated inflammatory diseases. However, the existing approach has limitations in terms of exosome size, composition, and delivery route, which can impact efficacy and safety. The present inventive concept addresses these limitations by introducing specific size and composition requirements, targeted delivery devices, and monitoring methods to enhance treatment outcomes.

The new inventive concept encompasses a system, method, and composition for treating immune-mediated inflammatory diseases using mesenchymal stem cell-derived exosomes with specific characteristics. The exosomes have a diameter between about 150 and about 300 nm and comprise thrombospondin-1 (TSP-1) and low TGF-β levels. A delivery device configured for targeted administration via a specific route is also disclosed. Furthermore, a method for enhancing exosome efficacy by modifying their molecular weight and composition is presented. Additionally, a device for isolating exosomes with improved purity and a method for monitoring treatment efficacy using biomarkers are introduced.

The new inventive concept introduces specific size and composition requirements for the exosomes, targeted delivery devices, and monitoring methods, which are not disclosed in the original patent. The combination of these features provides a novel and non-obvious solution for treating immune-mediated inflammatory diseases.

Alternative embodiments of the inventive concept may include varying the exosome size, composition, and delivery route to suit specific disease indications or patient populations. Additionally, different therapeutic agents or biomarkers could be used in conjunction with the exosomes to enhance treatment outcomes.

The enhanced mesenchymal stem cell-derived exosomes have significant commercial potential in the treatment of immune-mediated inflammatory diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. The targeted delivery and monitoring capabilities of the inventive concept may also expand its market reach to include personalized medicine and precision healthcare applications.